Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting.

abstract：OBJECTIVES:To describe treatment patterns and healthcare burden among individuals with suspected pulmonary arterial hypertension (PAH), as identified through a practice guideline-based healthcare claims algorithm. METHODS:Adults with evidence of PAH from 1 January 2004 (commercial and Medicaid) or 1 July 2006 (Medicar...

journal_title：Journal of medical economics

authors： Copher R,Cerulli A,Watkins A,Laura Monsalvo M

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVES:The purpose of this study is to report on long-term treatment patterns in a back pain population and to consider whether these may be considered as reflective of under-treatment of pain or poor pain control. METHODS:Data are from a commissioned recontact SELECT survey of persons who had previously reported ...

journal_title：Journal of medical economics

authors： Langley PC,Liedgens H

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:To estimate the lifetime economic consequences of glaucoma in France. METHODS:A Markov model estimated the average discounted outcome and cost of glaucoma treatment over a patient's lifetime. Clinical states were defined as first- to fourth-line drugs, no treatment, laser therapy, surgery, blindness and deat...

journal_title：Journal of medical economics

authors： Philippe Nordmann J,Lafuma A,Berdeaux G

更新日期：2009-03-01 00:00:00

abstract：:Background: IVF is now a wide spread procedure globally, and currently 65 countries report annually all or part of their IVF/ICSI cycles, from which the International Committee Monitoring progress in Assisted Reproduction Technology (ICMART) published its report. There is considerable variation in the utilization (num...

journal_title：Journal of medical economics

authors： Lass A,Chaudary W,Lass G

更新日期：2019-09-01 00:00:00

abstract：OBJECTIVE:This study evaluated infection-related hospitalization risk and cost in tumor necrosis factor inhibitor (TNFi)-experienced and targeted DMARD (tDMARD) naïve rheumatoid arthritis (RA) patients that were treated with abatacept, TNFi, or other non-TNFi. METHODS:This retrospective study used 100% Medicare Fee-fo...

journal_title：Journal of medical economics

authors： Patel V,Pulungan Z,Shah A,Kambhampati M,Lobo F,Petrilla A

更新日期：2021-01-27 00:00:00

abstract：OBJECTIVES:Atazanavir (ATV) and darunavir (DRV) are protease inhibitors approved for HIV treatment in combination with ritonavir (/r). The objectives of this study were to compare persistence (time to treatment discontinuation/modification), adherence, and healthcare costs among patients with human immunodeficiency vir...

journal_title：Journal of medical economics

authors： Farr AM,Johnston SS,Ritchings C,Brouillette M,Rosenblatt L

更新日期：2016-01-01 00:00:00

abstract：:Background: Guidelines recommend febrile neutropenia (FN) prophylaxis following myelotoxic chemotherapy with either daily injections of filgrastim (Neupogen®) or biosimilar filgrastim-sndz (Zarzio/Zarxio®), single-injection pegfilgrastim (Neulasta®), or pegfilgrastim administered through an on-body injector (PEG-OBI; ...

journal_title：Journal of medical economics

authors： McBride A,Krendyukov A,Mathieson N,Campbell K,Balu S,Natek M,MacDonald K,Abraham I

更新日期：2020-01-01 00:00:00

abstract：OBJECTIVE:This study evaluated the overall burden of illness of chemotherapy-induced nausea and vomiting (CINV) and associated all-cause costs from a hospital's perspective (costs to the hospital) in patients with cancer treated with chemotherapy (CT) in the US hospital outpatient setting. METHODS:Patients with a canc...

journal_title：Journal of medical economics

authors： Craver C,Gayle J,Balu S,Buchner D

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVE:The objective of the current study was to propose an alternative method for measuring individual operator and peer volumes to use as predictors for adverse outcomes. STUDY DESIGN:A retrospective analysis was performed to assess the volume-outcome relationship for percutaneous coronary intervention (PCI) perf...

journal_title：Journal of medical economics

authors： Xie Y,Rizzo JA,Brown DL

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Global budget (GB) is considered one of the most important payment methods available. Since a new round of healthcare system reforms in 2009, the Chinese government has been paying attention to this prospective payment. However, it is unclear whether GB has influenced cost control and how it works in rural C...

journal_title：Journal of medical economics

authors： He R,Miao Y,Ye T,Zhang Y,Tang W,Li Z,Zhang L

更新日期：2017-09-01 00:00:00

abstract：OBJECTIVE:The only effective treatment for severe aortic stenosis (AS) is valve replacement. However, many patients with co-existing conditions are ineligible for surgical valve replacement, historically leaving medical management (MM) as the only option which has a poor prognosis. Transcatheter Aortic Valve Replacemen...

journal_title：Journal of medical economics

authors： Hancock-Howard RL,Feindel CM,Rodes-Cabau J,Webb JG,Thompson AK,Banz K

更新日期：2013-01-01 00:00:00

abstract：AIMS:Six Delta is a six-dimensional independent platform for outcome-based pricing/contracting. The six dimensions have been described separately: (δ1) cost-effectiveness analysis and cost-utility analysis-based pricing; (δ2) willingness-to-pay-based pricing; (δ3) reference-based pricing; (δ4) safety-based pricing; (δ5...

journal_title：Journal of medical economics

authors： Alkhatib NS,McBride A,Slack M,Bhattacharjee S,Erstad B,Ramos K,Abraham I

更新日期：2020-11-01 00:00:00

abstract：BACKGROUND:Systemic Candida infections (SCI) occur predominantly in intensive care unit patients and are a common cause of morbidity and mortality. Recently, changes in Candida epidemiology with an increasing prevalence of SCI caused by Candida non-albicans species have been reported. Resistance to fluconazole and azol...

journal_title：Journal of medical economics

authors： Masterton RG,Casamayor M,Musingarimi P,van Engen A,Zinck R,Odufowora-Sita O,Odeyemi IA

更新日期：2013-11-01 00:00:00

abstract：:Aims: Due to the lack of studies evaluating compliance or persistence with Alzheimer's Disease (AD) treatment outside High-Income Countries (HICs), this study aimed to assess compliance, persistence, and factors associated with non-compliance and non-persistence by utilizing existing "real-world" information from mult...

journal_title：Journal of medical economics

authors： Kongpakwattana K,Dilokthornsakul P,Dejthevaporn C,Pattanaprateep O,Chaiyakunapruk N

更新日期：2019-01-01 00:00:00

abstract：OBJECTIVE:In the phase III SECURE trial, isavuconazole was non-inferior to voriconazole for all-cause mortality for the primary treatment of invasive mold disease (IMD) caused by Aspergillus spp. and other filamentous fungi. This analysis assessed whether hospital resource utilization was different between patients tre...

journal_title：Journal of medical economics

authors： Horn D,Goff D,Khandelwal N,Spalding J,Azie N,Shi F,Franks B,Shorr AF

更新日期：2016-07-01 00:00:00

abstract：OBJECTIVE:To estimate the cost-effectiveness of ipilimumab (3 mg/kg) compared with best supportive care (BSC) in pre-treated advanced melanoma patients. METHODS:The analysis was based on a US payer perspective and lifetime time horizon. A three-state Markov model was developed representing clinical outcomes, quality-o...

journal_title：Journal of medical economics

authors： Barzey V,Atkins MB,Garrison LP,Asukai Y,Kotapati S,Penrod JR

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVES:To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in infants with haemodynamically significant congenital heart disease (CHD) in the German healthcare setting. STUDY DESIG...

journal_title：Journal of medical economics

authors： Nuijten M,Lebmeier M,Wittenberg W

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:To assess the cost-effectiveness of insulin detemir compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin treatment in people with type 2 diabetes mellitus (T2DM) in Denmark, Finland, Norway, and Sweden. METHODS:Efficacy and safety data were derived from a 20-week multi-centre random...

journal_title：Journal of medical economics

authors： Ridderstråle M,Jensen MM,Gjesing RP,Niskanen L

更新日期：2013-01-01 00:00:00

abstract：AIM:Disease-modifying therapies (DMTs) impact the natural history of relapsing forms of multiple sclerosis (RRMS) by reducing annual relapse rates and slowing disability progression. The effect of DMTs on indirect costs has not been consistently explored in cost-effectiveness studies thus far. The value to patients of ...

journal_title：Journal of medical economics

authors： Frasco MA,Shih T,Incerti D,Diaz Espinosa O,Vania DK,Thomas N

更新日期：2017-10-01 00:00:00

abstract：OBJECTIVES:The first objective was to assess the effect of the chondroitin 4 and 6 sulphate (CS) on health-related quality of life using utility values in patients with knee osteoarthritis (OA) during a 24-month treatment course. The second objective was, using these data, to conduct economic analyses. METHODS:Data fr...

journal_title：Journal of medical economics

authors： Bruyère O,Scholtissen S,Neuprez A,Hiligsmann M,Toukouki A,Reginster JY

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:Duloxetine is indicated for treatment of major depressive disorders in the UK. While clinical trials have documented its clinical effectiveness, little is known regarding the relationship between duloxetine use and healthcare utilization in community practice. This study quantifies the impact of treatment wit...

journal_title：Journal of medical economics

authors： Shi N,Cao Z,Durden E,Schacht A,Torres A,Happich M

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVE:Allergic rhinitis (AR) is a chronic disease with a substantial clinical and economic burden. This study estimated the potential budget impact (BI) associated with market entry of Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use ('5...

journal_title：Journal of medical economics

authors： Ivanova JI,Kelkar S,King S,Birnbaum HG,Hocker S,Phipps R,Lankow R

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Currently the majority of cancer deaths occur in low- and middle-income countries, where there are appreciable funding concerns. In Kenya, most patients currently pay out of pocket for treatment, and those who are insured are generally not covered for the full costs of treatment. This places a considerable b...

journal_title：Journal of medical economics

authors： Atieno OM,Opanga S,Martin A,Kurdi A,Godman B

更新日期：2018-09-01 00:00:00

abstract：OBJECTIVE:This analysis was conducted to compare the direct medical costs of treatment with darbepoetin alfa every 3 weeks (Q3W) and epoetin alfa every week (QW) in patients with chemotherapy-induced anaemia (CIA) from the payer's perspective. METHODS:An analysis was conducted from a US health plan perspective to comp...

journal_title：Journal of medical economics

authors： Rubin RJ,Glaspy JA,Adams JL,Mafilios MS,Wang SM,Viswanathan HN,Kallich JD

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVE:In patients with significant mitral regurgitation (MR) at high risk of mortality and morbidity from mitral valve surgery, transcatheter mitral valve repair with the MitraClip System is associated with a reduction in MR and improved quality-of-life and functional status compared with baseline. The objective wa...

journal_title：Journal of medical economics

authors： Cameron HL,Bernard LM,Garmo VS,Hernandez JB,Asgar AW

更新日期：2014-08-01 00:00:00

abstract：OBJECTIVE:To assess the economic impact of initial and repeat hospitalizations associated with acute coronary syndrome (ACS) over 1 year (2009). DESIGN AND METHODS:National- and state-level data on length of stay (LOS) and related charges for ACS-associated hospital admissions were assessed using two Healthcare Utiliz...

journal_title：Journal of medical economics

authors： LaMori JC,Shoheiber O,Dudash K,Crivera C,Mody SH

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates of up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, these are a concern to health authorities especially given the low age of onset. Consequently, there is a need to treat BPD patients w...

journal_title：Journal of medical economics

authors： Godman B

更新日期：2015-01-01 00:00:00

abstract：OBJECTIVE:The purpose of this study was to determine the cost effectiveness (from a payer's perspective) of adding clostridial collagenase ointment (CCO) to selective debridement compared with selective debridement alone (non-CCO) in the treatment of stage IV pressure ulcers among patients identified from the US Wound ...

journal_title：Journal of medical economics

authors： Carter MJ,Gilligan AM,Waycaster CR,Schaum K,Fife CE

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:In the last decade, the number of new agents, including monoclonal antibodies, being developed to treat metastatic colorectal cancer (mCRC) increased rapidly. While improving outcomes, these new treatments also have distinct and known safety profiles with toxicities that may require hospitalizations. However...

journal_title：Journal of medical economics

authors： Overbeek JA,Zhao Z,van Herk-Sukel MP,Barber BL,Gao S,Herings RM

更新日期：2011-01-01 00:00:00

abstract：:Aims: Allopurinol is the most common urate lowering therapy (ULT) used to treat gout but may cause life-threatening severe cutaneous adverse reactions (SCAR) in a small number of patients. Risk of SCAR is increased for patients with the HLA-B*58:01 genotype. When alternative ULT is required, febuxostat or probenecid a...

journal_title：Journal of medical economics

authors： Pruis SL,Jeon YK,Pearce F,Thong BY,Aziz MIA

更新日期：2020-08-01 00:00:00